The Reduction in Endpoints in Non–insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL) study showed the renal protective effect of losartan in patients with diabetic nephropathy, which resulted in the reduction of proteinuria and an improvement in cardiovascular outcomes36. The gene discussed is AGT; the disease is diabetes mellitus.